Rapid Tested positive again 10 days after testing; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Rapid Tested positive again 10 days after testing) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19.    The patient's past medical history included Allergy. Concurrent medical conditions included High cholesterol. Concomitant products included ATORVASTATIN CALCIUM (ATORVASTIN) for an unknown indication.   On 05-May-2022 at 12:00 PM, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-May-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. In May 2022,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced COVID-19 (Rapid Tested positive again 10 days after testing). At the time of the report, COVID-19 (Rapid Tested positive again 10 days after testing) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In May 2022, SARS-CoV-2 test: negative (Negative) negative. On 22-May-2022, SARS-CoV-2 test: positive (Positive) Rapid Tested positive.         The patient was taking other medications/products within 2 weeks of starting COVID-19 treatment.  The patient tested positive again 10 days after testing negative 3 days before after running 5 days of paxlovid.  Treatment information was not provided.  Company Comment: This spontaneous case concerns an adult male patient of unknown age with no relevant medical history who experienced the unexpected, non-serious adverse event of special interest of COVID-19 which occurred on the same month after receiving the fourth dose of mRNA-1273 vaccine. There was no information regarding the first three doses of COVID-19 vaccine. Patient developed COVID-19 on unspecified date and was treated with 5-day course of Nirmatrelvir, Ritonavir (Paxlovid). He tested negative for COVID-19 on unspecified date but re-tested positive 10 days after having a negative result. The clinical course, diagnostic investigations, and treatment details after recurrence of positive test were not reported. The benefit-risk relationship of mRNA-1273 is not affected by this report.   Reporter did not allow further contact; Sender's Comments: This spontaneous case concerns an adult male patient of unknown age with no relevant medical history who experienced the unexpected, non-serious adverse event of special interest of COVID-19 which occurred on the same month after receiving the fourth dose of mRNA-1273 vaccine. There was no information regarding the first three doses of COVID-19 vaccine. Patient developed COVID-19 on unspecified date and was treated with 5-day course of Nirmatrelvir, Ritonavir (Paxlovid). He tested negative for COVID-19 on unspecified date but re-tested positive 10 days after having a negative result. The clinical course, diagnostic investigations, and treatment details after recurrence of positive test were not reported. The benefit-risk relationship of mRNA-1273 is not affected by this report.